(Q42502915)

1 November 2017

Osteoprotegerin and rank ligand expression in prostate cancer (English)

1 reference

1 November 2017

1 reference

Brown JM

1

1 reference

1 November 2017

Corey E

2

1 reference

1 November 2017

Lee ZD

3

1 reference

1 November 2017

True LD

4

1 reference

1 November 2017

Yun TJ

5

1 reference

1 November 2017

Tondravi M

6

1 reference

1 November 2017

Vessella RL

7

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

1 November 2017

1 reference

1 November 2017

57

1 reference

1 November 2017

611-616

1 reference

1 November 2017

4

1 reference

Morphometric evidence for bone resorption and replacement in prostate cancer

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

RANK is essential for osteoclast and lymph node development

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Bone metastases: pathophysiology and management policy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901122-5

7 January 2021

10.1016/S0090-4295(00)01122-5

Identifiers

DOI

1 reference

1 November 2017

1 reference